Investors & News

Denali Therapeutics Inc. (Nasdaq: DNLI) is a biotechnology company pioneering a new class of biotherapeutics designed to cross the blood-brain barrier using our proprietary TransportVehicle^TM platform. With a clinically validated delivery platform and a growing portfolio of therapeutic candidates across all stages of development, we are advancing toward our goal of delivering effective medicines to transform the lives of people living with neurodegenerative, lysosomal and other serious diseases.

View All

Market Cap

Volume

Today's Open

Previous Close

Today's High

Today's Low

52 Week High

52 Week Low

Minimum 15 minutes delayed. Source: LSEG

Analyst Coverage

View detailed list of firms and analysts.
View Coverage
SEC Filings

View, download, and share all SEC Filing documents.
View Documents
Corporate Governance

View, download, and share Corporate Governance documents.
View Documents

Denali Therapeutics Inc. was incorporated in Delaware in October 2013

Denali is headquartered in South San Francisco, CA.

Denali's fiscal year ends December 31st

Ernst & Young LLP is Denali's independent registered public accounting firm

Denali is traded on the NASDAQ Global Select Stock Market under the ticker symbol "DNLI"

Denali initial public offering occurred on December 8, 2017

24823R 105

Broadridge Financial Solutions

5 Dakota Drive, Suite 300,
Lake Success, NY 11042
+1 800 353 0103

https://www.broadridge.com/contact

Electronic copies of our Annual Report and other periodic reports are available on this website. If you would like to request paper copies of the Annual Report or other periodic reports, send your request in writing to:

Denali Therapeutics Inc.

Attn: Corporate Secretary

151 Oyster Point Blvd

South San Francisco, CA 94080

Please contact InvestorRelations@dnli.com for additional questions or inquiries.

Investors & News

Press Releases

Denali Therapeutics to Give Opening Plenary Address at Alzheimer’s Association International Conference (AAIC) 2026 and Highlight Breakthroughs in Delivering Biologic Therapies Across Blood-Brain Barrier

Denali Therapeutics Enters Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $195 Million

Biogen and Denali Therapeutics Provide Update on Phase 2b LUMA Study of BIIB122 (DNL151) in Early-Stage Parkinson’s Disease

Denali Therapeutics Reports First Quarter 2026 Financial Results and Business Highlights

Recent Events

Corporate Presentation

FAQs

Sign up for email alerts

Investors & News

Press Releases

Denali Therapeutics to Give Opening Plenary Address at Alzheimer’s Association International Conference (AAIC) 2026 and Highlight Breakthroughs in Delivering Biologic Therapies Across Blood-Brain Barrier

Denali Therapeutics Enters Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $195 Million

Biogen and Denali Therapeutics Provide Update on Phase 2b LUMA Study of BIIB122 (DNL151) in Early-Stage Parkinson’s Disease

Denali Therapeutics Reports First Quarter 2026 Financial Results and Business Highlights

Recent Events

Corporate Presentation

FAQs

Where is Denali incorporated?

Where is Denali's corporate headquarters?

When is Denali's fiscal year-end?

Who is Denali's independent registered public accounting firm?

On which exchange is Denali listed, what is the ticker symbol, and when did Denali go public?

What is the cusip number for Denail's common stock?

Who is Denali's transfer agent and how do I contact them?

How can I get a copy of your annual report or other periodic reports?

How do I contact Denali with additional questions or inquiries?

Sign up for email alerts